Eight-year data confirm long-term durability of edwards' resilia tissue

Cairo--(business wire)--edwards lifesciences (nyse: ew) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary resilia tissue technology have significantly improved long-term outcomes compared to those receiving non-resilia tissue bioprosthetic valves. for more than 65 years, edwards has been the leader in heart valve innovations. to create a more durable heart valve, edwards developed the resilia tissue technology more than two d.
EW Ratings Summary
EW Quant Ranking